{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:20:39Z","timestamp":1784956839023,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81460569"],"award-info":[{"award-number":["81460569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s13318-019-00578-4","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T18:10:35Z","timestamp":1569003035000},"page":"135-149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population"],"prefix":"10.1007","volume":"45","author":[{"given":"Ren","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-0240","authenticated-orcid":false,"given":"Tao-tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Jiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-le","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"issue":"1","key":"578_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14740330903413514","volume":"9","author":"ED Hermsen","year":"2010","unstructured":"Hermsen ED, Hanson M, Sankaranarayanan J, et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf. 2010;9(1):9\u201314. \nhttps:\/\/doi.org\/10.1517\/14740330903413514\n\n.","journal-title":"Expert Opin Drug Saf."},{"key":"578_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01293-17","author":"NA Finch","year":"2017","unstructured":"Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother. 2017. \nhttps:\/\/doi.org\/10.1128\/aac.01293-17\n\n.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"578_CR3","first-page":"21","volume":"31","author":"JH Martin","year":"2010","unstructured":"Martin JH, Norris R, Barras M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. Clin Biochem Rev. 2010;31(1):21\u20134.","journal-title":"Clin Biochem Rev."},{"issue":"3","key":"578_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10156-013-0599-4","volume":"19","author":"K Matsumoto","year":"2013","unstructured":"Matsumoto K, Takesue Y, Ohmagari N, et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2013;19(3):365\u201380. \nhttps:\/\/doi.org\/10.1007\/s10156-013-0599-4\n\n.","journal-title":"J Infect Chemother."},{"issue":"11","key":"578_CR5","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","volume":"71","author":"ZK Ye","year":"2016","unstructured":"Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020\u20135. \nhttps:\/\/doi.org\/10.1093\/jac\/dkw254\n\n.","journal-title":"J Antimicrob Chemother."},{"key":"578_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0534-2","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Gao F, Chen C, et al. Development of a population pharmacokinetic model of vancomycin and its application in Chinese geriatric patients with pulmonary infections. Eur J Drug Metab Pharmacokinet. 2018. \nhttps:\/\/doi.org\/10.1007\/s13318-018-0534-2\n\n.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"9","key":"578_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s00228-012-1259-9","volume":"68","author":"S Elyasi","year":"2012","unstructured":"Elyasi S, Khalili H, Dashti-Khavidaki S, et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol. 2012;68(9):1243\u201355. \nhttps:\/\/doi.org\/10.1007\/s00228-012-1259-9\n\n.","journal-title":"Eur J Clin Pharmacol."},{"issue":"suppl_2","key":"578_CR8","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1093\/cid\/ciy680","volume":"67","author":"X Liang","year":"2018","unstructured":"Liang X, Fan Y, Yang M, et al. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin Infect Dis. 2018;67(suppl_2):S249\u201355. \nhttps:\/\/doi.org\/10.1093\/cid\/ciy680\n\n.","journal-title":"Clin Infect Dis."},{"issue":"3","key":"578_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5414\/CP201776","volume":"51","author":"YC Chen","year":"2013","unstructured":"Chen YC, Feng JF, Li B, et al. Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations. Int J Clin Pharmacol Ther. 2013;51(3):161\u20139. \nhttps:\/\/doi.org\/10.5414\/CP201776\n\n.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"578_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5414\/CP201842","volume":"51","author":"C Deng","year":"2013","unstructured":"Deng C, Liu T, Zhou T, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2013;51(5):407\u201315. \nhttps:\/\/doi.org\/10.5414\/CP201842\n\n.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"578_CR11","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11096-015-0157-5","volume":"37","author":"F Keshavarzi","year":"2015","unstructured":"Keshavarzi F. Renal function overestimation in underweight and\/or non-ambulatory patients. Int J Clin Pharm. 2015;37(5):675\u20137. \nhttps:\/\/doi.org\/10.1007\/s11096-015-0157-5\n\n.","journal-title":"Int J Clin Pharm."},{"issue":"3","key":"578_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/01.ftd.0000211805.89440.3d","volume":"28","author":"J Hermida","year":"2006","unstructured":"Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit. 2006;28(3):326\u201331. \nhttps:\/\/doi.org\/10.1097\/01.ftd.0000211805.89440.3d\n\n.","journal-title":"Ther Drug Monit"},{"issue":"7","key":"578_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clinbiochem.2007.01.008","volume":"40","author":"G Okamoto","year":"2007","unstructured":"Okamoto G, Sakamoto T, Kimura M, et al. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem. 2007;40(7):485\u201390. \nhttps:\/\/doi.org\/10.1016\/j.clinbiochem.2007.01.008\n\n.","journal-title":"Clin Biochem"},{"issue":"2","key":"578_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1128\/AAC.00661-09","volume":"54","author":"A Tanaka","year":"2010","unstructured":"Tanaka A, Aiba T, Otsuka T, et al. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother. 2010;54(2):778\u201382. \nhttps:\/\/doi.org\/10.1128\/AAC.00661-09\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"578_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.clinbiochem.2016.11.024","volume":"50","author":"EL Barr","year":"2017","unstructured":"Barr EL, Maple-Brown LJ, Barzi F, et al. Comparison of creatinine and cystatin C based eGFR in the estimation of glomerular filtration rate in Indigenous Australians: the eGFR study. Clin Biochem. 2017;50(6):301\u20138. \nhttps:\/\/doi.org\/10.1016\/j.clinbiochem.2016.11.024\n\n.","journal-title":"Clin Biochem"},{"issue":"8","key":"578_CR16","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/ndt\/gfx272","volume":"33","author":"J Bjork","year":"2018","unstructured":"Bjork J, Grubb A, Gudnason V, et al. Comparison of glomerular filtration rate estimating equations derived from creatinine and cystatin C: validation in the Age, Gene\/Environment Susceptibility-Reykjavik elderly cohort. Nephrol Dial Transplant. 2018;33(8):1380\u20138. \nhttps:\/\/doi.org\/10.1093\/ndt\/gfx272\n\n.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"578_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1515\/cclm-2017-0563","volume":"56","author":"J Bjork","year":"2018","unstructured":"Bjork J, Back SE, Ebert N, et al. GFR estimation based on standardized creatinine and cystatin C: a European multicenter analysis in older adults. Clin Chem Lab Med. 2018;56(3):422\u201335. \nhttps:\/\/doi.org\/10.1515\/cclm-2017-0563\n\n.","journal-title":"Clin Chem Lab Med"},{"key":"578_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13071","author":"TT Liu","year":"2019","unstructured":"Liu TT, Pang HM, Jing L, et al. A population pharmacokinetic model of vancomycin for dose individualization based on serum cystatin C as a marker of renal function. J Pharm Pharmacol. 2019. \nhttps:\/\/doi.org\/10.1111\/jphp.13071\n\n.","journal-title":"J Pharm Pharmacol"},{"issue":"10","key":"578_CR19","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1093\/ndt\/gfg349","volume":"18","author":"FJ Hoek","year":"2003","unstructured":"Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant. 2003;18(10):2024\u201331. \nhttps:\/\/doi.org\/10.1093\/ndt\/gfg349\n\n.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"578_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341. \nhttps:\/\/doi.org\/10.1159\/000180580\n\n.","journal-title":"Nephron."},{"issue":"6","key":"578_CR21","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/jcpt.12092","volume":"38","author":"C Deng","year":"2013","unstructured":"Deng C, Liu T, Wu K, et al. Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients. J Clin Pharm Ther. 2013;38(6):480\u20139. \nhttps:\/\/doi.org\/10.1111\/jcpt.12092\n\n.","journal-title":"J Clin Pharm Ther"},{"key":"578_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02543-18","author":"T Guo","year":"2019","unstructured":"Guo T, van Hest RM, Roggeveen LF, et al. External evaluation of population pharmacokinetic models of vancomycin in large cohorts of intensive care patients. Antimicrob Agents Chemother. 2019. \nhttps:\/\/doi.org\/10.1128\/AAC.02543-18\n\n.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"578_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00228-018-2521-6","volume":"74","author":"C Hu","year":"2018","unstructured":"Hu C, Yin WJ, Li DY, et al. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes. Eur J Clin Pharmacol. 2018;74(11):1437\u201347. \nhttps:\/\/doi.org\/10.1007\/s00228-018-2521-6\n\n.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"578_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/bcp.12830","volume":"81","author":"CY Zhao","year":"2016","unstructured":"Zhao CY, Jiao Z, Mao JJ, et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients. Br J Clin Pharmacol. 2016;81(5):891\u2013907. \nhttps:\/\/doi.org\/10.1111\/bcp.12830\n\n.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"578_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/jac\/dkv372","volume":"71","author":"SE Medellin-Garibay","year":"2016","unstructured":"Medellin-Garibay SE, Ortiz-Martin B, Rueda-Naharro A, et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471\u20139. \nhttps:\/\/doi.org\/10.1093\/jac\/dkv372\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"578_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/phar.1531","volume":"35","author":"ED Adane","year":"2015","unstructured":"Adane ED, Herald M, Koura F. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy. 2015;35(2):127\u201339. \nhttps:\/\/doi.org\/10.1002\/phar.1531\n\n.","journal-title":"Pharmacotherapy."},{"issue":"6","key":"578_CR27","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/AAC.01708-10","volume":"55","author":"J Roberts","year":"2011","unstructured":"Roberts J, Taccone F, Udy A, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011;55(6):2704\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"578_CR28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5414\/CPP48525","volume":"48","author":"JL Sanchez","year":"2010","unstructured":"Sanchez JL, Dominguez AR, Lane JR, et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48(8):525\u201333.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"578_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2125.2010.03679.x","volume":"70","author":"N Revilla","year":"2010","unstructured":"Revilla N, Martin-Suarez A, Perez MP, et al. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic\/pharmacodynamic simulation. Br J Clin Pharmacol. 2010;70(2):201\u201312. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2010.03679.x\n\n.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"578_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/jac\/dkp085","volume":"63","author":"AH Thomson","year":"2009","unstructured":"Thomson AH, Staatz CE, Tobin CM, et al. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother. 2009;63(5):1050\u20137. \nhttps:\/\/doi.org\/10.1093\/jac\/dkp085\n\n.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"578_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1365-2125.2005.02547.x","volume":"61","author":"CE Staatz","year":"2006","unstructured":"Staatz CE, Byrne C, Thomson AH. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. Br J Clin Pharmacol. 2006;61(2):164\u201376. \nhttps:\/\/doi.org\/10.1111\/j.1365-2125.2005.02547.x\n\n.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"578_CR32","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2710.2006.00762.x","volume":"31","author":"P Llopis-Salvia","year":"2006","unstructured":"Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J Clin Pharm Ther. 2006;31(5):447\u201354. \nhttps:\/\/doi.org\/10.1111\/j.1365-2710.2006.00762.x\n\n.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"578_CR33","doi-asserted-by":"publisher","first-page":"4934","DOI":"10.1128\/aac.49.12.4934-4941.2005","volume":"49","author":"DS Buelga","year":"2005","unstructured":"Buelga DS, de del Mar Fernandez M, Herrera EV, et al. Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrob Agents Chemother. 2005;49(12):4934\u201341. \nhttps:\/\/doi.org\/10.1128\/aac.49.12.4934-4941.2005\n\n.","journal-title":"Antimicrob Agents Chemother."},{"issue":"2","key":"578_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00007691-199804000-00003","volume":"20","author":"M Yasuhara","year":"1998","unstructured":"Yasuhara M, Iga T, Zenda H, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20(2):139\u201348.","journal-title":"Ther Drug Monit"},{"key":"578_CR35","doi-asserted-by":"publisher","first-page":"762649","DOI":"10.1100\/2012\/762649","volume":"2012","author":"TA Purwonugroho","year":"2012","unstructured":"Purwonugroho TA, Chulavatnatol S, Preechagoon Y, et al. Population pharmacokinetics of vancomycin in Thai patients. Sci World J. 2012;2012:762649. \nhttps:\/\/doi.org\/10.1100\/2012\/762649\n\n.","journal-title":"Sci World J"},{"issue":"11","key":"578_CR36","first-page":"1528","volume":"49","author":"XR He","year":"2014","unstructured":"He XR, Liu ZH, Ji SM, et al. Population pharmacokinetics of vancomycin and prediction of pharmacodynamics in the Chinese people. Yao Xue Xue Bao. 2014;49(11):1528\u201335.","journal-title":"Yao Xue Xue Bao."},{"issue":"1","key":"578_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00228-015-1952-6","volume":"72","author":"WW Lin","year":"2016","unstructured":"Lin WW, Wu W, Jiao Z, et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2016;72(1):29\u201337. \nhttps:\/\/doi.org\/10.1007\/s00228-015-1952-6\n\n.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"578_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jfma.2015.05.017","volume":"115","author":"CC Wu","year":"2016","unstructured":"Wu CC, Shen LJ, Hsu LF, et al. Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc. 2016;115(7):560\u201370. \nhttps:\/\/doi.org\/10.1016\/j.jfma.2015.05.017\n\n.","journal-title":"J Formos Med Assoc"},{"key":"578_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.57","author":"XW Ji","year":"2017","unstructured":"Ji XW, Ji SM, He XR, et al. Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. Acta Pharmacol Sin. 2017. \nhttps:\/\/doi.org\/10.1038\/aps.2017.57\n\n.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"578_CR40","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/0010-4809(72)90051-1","volume":"5","author":"LB Sheiner","year":"1972","unstructured":"Sheiner LB, Rosenberg B, Melmon KL. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res. 1972;5(5):411\u201359.","journal-title":"Comput Biomed Res"},{"issue":"5","key":"578_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF01061728","volume":"5","author":"LB Sheiner","year":"1977","unstructured":"Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm. 1977;5(5):445\u201379.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"11","key":"578_CR42","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3345\/kjp.2015.58.11.421","volume":"58","author":"JE Shin","year":"2015","unstructured":"Shin JE, Lee SM, Eun HS, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in neonate. Korean J Pediatr. 2015;58(11):421\u20136. \nhttps:\/\/doi.org\/10.3345\/kjp.2015.58.11.421\n\n.","journal-title":"Korean J Pediatr."},{"issue":"3","key":"578_CR43","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/cc13899","volume":"18","author":"EN Frazee","year":"2014","unstructured":"Frazee EN, Rule AD, Herrmann SM, et al. Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: a cohort study. Crit Care. 2014;18(3):R110. \nhttps:\/\/doi.org\/10.1186\/cc13899\n\n.","journal-title":"Crit Care"},{"issue":"11","key":"578_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.5414\/CPP45592","volume":"45","author":"A Tanaka","year":"2007","unstructured":"Tanaka A, Suemaru K, Otsuka T, et al. Hoek\u2019s formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int J Clin Pharmacol Ther. 2007;45(11):592\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"578_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12882-017-0637-z","volume":"18","author":"X Chi","year":"2017","unstructured":"Chi X, Li G, Wang Q, et al. CKD-EPI creatinine-cystatin C glomerular filtration rate estimation equation seems more suitable for Chinese patients with chronic kidney disease than other equations. BMC Nephrol. 2017;18(1):226.","journal-title":"BMC Nephrol."},{"issue":"7","key":"578_CR46","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1211\/jpp.62.07.0011","volume":"62","author":"A Suzuki","year":"2010","unstructured":"Suzuki A, Imanishi Y, Nakano S, et al. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol. 2010;62(7):901\u20137. \nhttps:\/\/doi.org\/10.1211\/jpp.62.07.0011\n\n.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"578_CR47","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0b013e31803bcfd2","volume":"29","author":"A Tanaka","year":"2007","unstructured":"Tanaka A, Suemaru K, Otsuka T, et al. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit. 2007;29(2):261\u20134. \nhttps:\/\/doi.org\/10.1097\/FTD.0b013e31803bcfd2\n\n.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"578_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/00365513.2010.546879","volume":"71","author":"A Grubb","year":"2011","unstructured":"Grubb A, Bjork J, Nyman U, et al. Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest. 2011;71(2):145\u20139. \nhttps:\/\/doi.org\/10.3109\/00365513.2010.546879\n\n.","journal-title":"Scand J Clin Lab Invest"},{"issue":"8","key":"578_CR49","first-page":"1367","volume":"50","author":"M Shigemura","year":"2012","unstructured":"Shigemura M, Konno S, Nasuhara Y, et al. Impact of asthmatic control status on serum cystatin C concentrations. Clin Chem Lab Med. 2012;50(8):1367\u201371.","journal-title":"Clin Chem Lab Med"},{"issue":"1\u20132","key":"578_CR50","first-page":"203","volume":"62","author":"JL Zhai","year":"2016","unstructured":"Zhai JL, Ge N, Zhen Y, et al. Corticosteroids significantly increase serum cystatin C concentration without affecting renal function in symptomatic heart failure. Clin Lab. 2016;62(1\u20132):203\u20137.","journal-title":"Clin Lab."},{"issue":"1","key":"578_CR51","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000469715","volume":"42","author":"TJ Pianta","year":"2017","unstructured":"Pianta TJ, Pickering JW, Succar L, et al. Dexamethasone modifies cystatin c-based diagnosis of acute kidney injury during cisplatin-based chemotherapy. Kidney Blood Press Res. 2017;42(1):62\u201375. \nhttps:\/\/doi.org\/10.1159\/000469715\n\n.","journal-title":"Kidney Blood Press Res."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-019-00578-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-019-00578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T23:46:41Z","timestamp":1600472801000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-019-00578-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s13318-019-00578-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]},"assertion":[{"value":"20 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by The National Natural Science Foundation of China under grant no. 81460569.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zhang Ren, Chen Ming, Lu Jiejiu, Lv Chunle and Liu Taotao have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures in this study were conducted in accordance with the 1964 Helsinki Declaration (and its amendments) and the guidelines of the ethics committee or institutional review board that approved the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}